Cellipont Bioservices

Cellipont Bioservices is a privately held, US-based CDMO focused exclusively on the cell therapy sector, positioning itself as a specialized partner for biotech companies. The company has established a significant operational footprint with a purpose-built, flexible cGMP manufacturing facility designed for clinical-scale production. With a leadership team experienced in cell therapy development and strategic collaborations with multiple technology and therapy developers, Cellipont is capitalizing on the growing demand for outsourced manufacturing in the advanced therapies space. Its business model is service-based, generating revenue through client contracts for development and manufacturing work.

Integrated CDMO services with a purpose-built cGMP facility featuring modular cleanrooms, automated closed-processing systems (e.g., Lonza Cocoon, Miltenyi Prodigy), and specialized capabilities for cell therapy development and manufacturing.

Cellipont competes in the cell therapy CDMO space against large, diversified giants like Lonza, Catalent, and Thermo Fisher Scientific, as well as other focused players like ElevateBio, Cryoport Systems, and RoslinCT. Its differentiation hinges on deep technical expertise in complex therapies like CAR-T, an agile, purpose-built facility, and a partnership-driven approach.